Biotech · Private company · New York, NY, US
Trigemx Bio, Inc.
SEC CIK 0001655846
Track this companyFree. Adds Trigemx Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials93 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- ElismetrepPhase 3 · Acute MigraineClinicalTrials.gov · fetched Nov 12, 2026
- ElismetrepPhase 3 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- Elismetrep (K-304) 10 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- Elismetrep (K-304) 2 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- Elismetrep (K-304) 20 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- Elismetrep (K-304) 5 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- K-645 10 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- K-645 100 mgPhase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- K-757 120 mg BID and K-833 100 mg BIDPhase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- K-757Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- K-757 and K-833Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- K-757 and K-833 BIDPhase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- K-757 and K-833 QDPhase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- K-757 and open-label sitagliptinPhase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePHASE3 · RECRUITING · started Oct 2, 2026ClinicalTrials.gov NCT07816367 · fetched Nov 12, 2026
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigrainePHASE3 · RECRUITING · started Aug 3, 2026ClinicalTrials.gov NCT07674654 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePHASE3 · RECRUITING · started Jul 1, 2026ClinicalTrials.gov NCT07645924 · fetched Nov 12, 2026
- A Study of K-645 in the Treatment of Multiple Migraine AttacksPHASE2 · TERMINATED · started Aug 13, 2025ClinicalTrials.gov NCT07116499 · fetched Nov 12, 2026
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigrainePHASE2 · COMPLETED · started Mar 11, 2025ClinicalTrials.gov NCT06848075 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesPHASE1 · COMPLETED · started Dec 7, 2023ClinicalTrials.gov NCT06305351 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833PHASE2 · COMPLETED · started Sep 15, 2023ClinicalTrials.gov NCT06019559 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesPHASE1 · COMPLETED · started Mar 13, 2023ClinicalTrials.gov NCT05890950 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese VolunteersPHASE1 · COMPLETED · started Sep 21, 2022ClinicalTrials.gov NCT05900531 · fetched Nov 12, 2026